3 búsqueda de la palabra clave 'Antifungal'

A global point prevalence survey of antimicrobial use in neonatal intensive care units: The no-more-antibiotics and resistance (NO-MAS-R) study    

Público ISBD Título : A global point prevalence survey of antimicrobial use in neonatal intensive care units: The no-more-antibiotics and resistance (NO-MAS-R) study Tipo de documento : documento electrónico Fecha de publicación : 2021 Títulos uniformes : eClinicalMedicine Idioma : Inglés (eng) Palabras clave : Global point prevalence study  Neonatal infection  Neonatal antimicrobial stewardship  Antibiotics  Antifungal Resumen : Background: Global assessment of antimicrobial agents prescribed to infants in the neonatal intensive care unit (NICU) may inform antimicrobial stewardship efforts. Methods: We conducted a one-day global point prevalence study of all antimicrobials provided to NICU infants. Demographic, clinical, and microbiologic data were obtained including NICU level, census, birth weight, gestational/chronologic age, diagnoses, antimicrobial therapy (reason for use; length of therapy), antimicrobial stewardship program (ASP), and 30-day in-hospital mortality. Findings: On July 1, 2019, 26% of infants (580/2,265; range, 0–100%; median gestational age, 33 weeks; median birth weight, 1800 g) in 84 NICUs (51, high-income; 33, low-to-middle income) from 29 countries (14, high-income; 15, low-to-middle income) in five continents received ≥1 antimicrobial agent (92%, antibacterial; 19%, antifungal; 4%, antiviral). The most common reasons for antibiotic therapy were “rule-out” sepsis (32%) and “culture-negative” sepsis (16%) with ampicillin (40%), gentamicin (35%), amikacin (19%), vancomycin (15%), and meropenem (9%) used most frequently. For definitive treatment of presumed/confirmed infection, vancomycin (26%), amikacin (20%), and meropenem (16%) were the most prescribed agents. Length of therapy for culture-positive and “culture-negative” infections was 12 days (median; IQR, 8–14) and 7 days (median; IQR, 5–10), respectively. Mortality was 6% (42%, infection-related). An NICU ASP was associated with lower rate of antibiotic utilization (p = 0·02). Interpretation: Global NICU antibiotic use was frequent and prolonged regardless of culture results. NICU-specific ASPs were associated with lower antibiotic utilization rates, suggesting the need for their implementation worldwide. Mención de responsabilidad : Pavel Prusakov, PharmD, Debra A. Goff, PharmD, Phillip S. Wozniak, BA, Azraa Cassim, BPharm, Catherine E.A. Scipion, MD, Soledad Urzua, MD, Andrea Ronchi, MD, Lingkong Zeng, MD, Oluwaseun Ladipo-Ajayi, MBChB, Noelia Aviles-Otero, MD, Chisom R. Udeigwe-Okeke, MBBS, Rimma Melamed, MD, Rita C. Silveira, MD,Cinzia Auriti, MD, Claudia Beltran-Arroyave, MD, Elena Zamora-Flores, MD, Maria Sanchez-Codez, MD, Eric S. Donkor, PhD, Satu Kekomaki, MD, Nicoletta Mainini, MD, Rosalba Vivas Trochez, MD, Jamalyn Casey, PharmD, Juan M. Graus, MD, Mallory Muller, PharmD, Sara Singh, MBBS, Yvette Loeffen, MD, María Eulalia Tamayo Perez, MD, Gloria Isabel Ferreyra, MD, Victoria Lima-Rogel, MD, Barbara Perrone, MD, Giannina Izquierdo, MD, María Cernada, MD, Sylvia Stoffella, PharmD, Sebastian Okwuchukwu Ekenze, MD, Concepcion de Alba-Romero, MD, Chryssoula Tzialla, MD, Jennifer T. Pham, PharmD, Kenichiro Hosoi, MD, Magdalena Cecilia Calero Consuegra, MD, Pasqua Betta, MD, O. Alvaro Hoyos, MD, Emmanuel Roi Referencia : EClinicalMedicine. 2021 Jan 29;32:100727. DOI (Digital Object Identifier) : 10.1016/j.eclinm.2021.100727 PMID : 33554094 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S2589537021000079 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5860 A global point prevalence survey of antimicrobial use in neonatal intensive care units: The no-more-antibiotics and resistance (NO-MAS-R) study [documento electrónico] . - 2021. Obra : eClinicalMedicine Idioma : Inglés (eng) Palabras clave : Global point prevalence study  Neonatal infection  Neonatal antimicrobial stewardship  Antibiotics  Antifungal Resumen : Background: Global assessment of antimicrobial agents prescribed to infants in the neonatal intensive care unit (NICU) may inform antimicrobial stewardship efforts. Methods: We conducted a one-day global point prevalence study of all antimicrobials provided to NICU infants. Demographic, clinical, and microbiologic data were obtained including NICU level, census, birth weight, gestational/chronologic age, diagnoses, antimicrobial therapy (reason for use; length of therapy), antimicrobial stewardship program (ASP), and 30-day in-hospital mortality. Findings: On July 1, 2019, 26% of infants (580/2,265; range, 0–100%; median gestational age, 33 weeks; median birth weight, 1800 g) in 84 NICUs (51, high-income; 33, low-to-middle income) from 29 countries (14, high-income; 15, low-to-middle income) in five continents received ≥1 antimicrobial agent (92%, antibacterial; 19%, antifungal; 4%, antiviral). The most common reasons for antibiotic therapy were “rule-out” sepsis (32%) and “culture-negative” sepsis (16%) with ampicillin (40%), gentamicin (35%), amikacin (19%), vancomycin (15%), and meropenem (9%) used most frequently. For definitive treatment of presumed/confirmed infection, vancomycin (26%), amikacin (20%), and meropenem (16%) were the most prescribed agents. Length of therapy for culture-positive and “culture-negative” infections was 12 days (median; IQR, 8–14) and 7 days (median; IQR, 5–10), respectively. Mortality was 6% (42%, infection-related). An NICU ASP was associated with lower rate of antibiotic utilization (p = 0·02). Interpretation: Global NICU antibiotic use was frequent and prolonged regardless of culture results. NICU-specific ASPs were associated with lower antibiotic utilization rates, suggesting the need for their implementation worldwide. Mención de responsabilidad : Pavel Prusakov, PharmD, Debra A. Goff, PharmD, Phillip S. Wozniak, BA, Azraa Cassim, BPharm, Catherine E.A. Scipion, MD, Soledad Urzua, MD, Andrea Ronchi, MD, Lingkong Zeng, MD, Oluwaseun Ladipo-Ajayi, MBChB, Noelia Aviles-Otero, MD, Chisom R. Udeigwe-Okeke, MBBS, Rimma Melamed, MD, Rita C. Silveira, MD,Cinzia Auriti, MD, Claudia Beltran-Arroyave, MD, Elena Zamora-Flores, MD, Maria Sanchez-Codez, MD, Eric S. Donkor, PhD, Satu Kekomaki, MD, Nicoletta Mainini, MD, Rosalba Vivas Trochez, MD, Jamalyn Casey, PharmD, Juan M. Graus, MD, Mallory Muller, PharmD, Sara Singh, MBBS, Yvette Loeffen, MD, María Eulalia Tamayo Perez, MD, Gloria Isabel Ferreyra, MD, Victoria Lima-Rogel, MD, Barbara Perrone, MD, Giannina Izquierdo, MD, María Cernada, MD, Sylvia Stoffella, PharmD, Sebastian Okwuchukwu Ekenze, MD, Concepcion de Alba-Romero, MD, Chryssoula Tzialla, MD, Jennifer T. Pham, PharmD, Kenichiro Hosoi, MD, Magdalena Cecilia Calero Consuegra, MD, Pasqua Betta, MD, O. Alvaro Hoyos, MD, Emmanuel Roi Referencia : EClinicalMedicine. 2021 Jan 29;32:100727. DOI (Digital Object Identifier) : 10.1016/j.eclinm.2021.100727 PMID : 33554094 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S2589537021000079 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5860

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001798	AC-2021-110	Archivo digital	Producción Científica	Artículos científicos	Disponible

Documentos electrónicos

2021-110 Adobe Acrobat PDF

Breakthrough Hormographiella aspergillata infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis: a case report and review / Isabel Cristina Ramírez Sánchez  

Público ISBD Título : Breakthrough Hormographiella aspergillata infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis: a case report and review Tipo de documento : documento electrónico Autores : Isabel Cristina Ramírez Sánchez, Fecha de publicación : 2020 Títulos uniformes : Mycopathologia Idioma : Inglés (eng) Palabras clave : Antifungal  Breakthrough  Hormographiella aspergillata  Pneumonia  Posaconazole  Prophylaxis Resumen : Breakthrough invasive infections occur in immunosuppressed patients while they are receiving antifungal agents for both prophylaxis and therapy. Under such conditions, unusual fungal infections emerge. Hormographiella aspergillata is considered an uncommon human pathogen and causes devastating infections. Here, we present a case report of necrotizing pneumonia caused by H. aspergillata as a breakthrough infection in a neutropenic patient and review all previous cases of H. aspergillata infection reported in the literature. Mención de responsabilidad : Ramírez-Sanchez Isabel Cristina, Agredo Diana, Arango Karen Referencia : Mycopathologia. 2020 Dec;185(6):1069-1076. DOI (Digital Object Identifier) : 10.1007/s11046-020-00488-z PMID : 32880829 En línea : https://link.springer.com/article/10.1007/s11046-020-00488-z Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5136 Breakthrough Hormographiella aspergillata infection in a patient with acute myeloid leukemia receiving posaconazole prophylaxis: a case report and review [documento electrónico] / Isabel Cristina Ramírez Sánchez,  . - 2020. Obra : Mycopathologia Idioma : Inglés (eng) Palabras clave : Antifungal  Breakthrough  Hormographiella aspergillata  Pneumonia  Posaconazole  Prophylaxis Resumen : Breakthrough invasive infections occur in immunosuppressed patients while they are receiving antifungal agents for both prophylaxis and therapy. Under such conditions, unusual fungal infections emerge. Hormographiella aspergillata is considered an uncommon human pathogen and causes devastating infections. Here, we present a case report of necrotizing pneumonia caused by H. aspergillata as a breakthrough infection in a neutropenic patient and review all previous cases of H. aspergillata infection reported in the literature. Mención de responsabilidad : Ramírez-Sanchez Isabel Cristina, Agredo Diana, Arango Karen Referencia : Mycopathologia. 2020 Dec;185(6):1069-1076. DOI (Digital Object Identifier) : 10.1007/s11046-020-00488-z PMID : 32880829 En línea : https://link.springer.com/article/10.1007/s11046-020-00488-z Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5136

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001396	AC-2020-073	Archivo digital	Producción Científica	Artículos científicos	Disponible

Fatal disseminated infection by Trichosporon asahii under voriconazole therapy in a patient with acute myeloid leukemia: a review of breakthrough infections by Trichosporon spp / Isabel Cristina Ramírez Sánchez  

Público ISBD Título : Fatal disseminated infection by Trichosporon asahii under voriconazole therapy in a patient with acute myeloid leukemia: a review of breakthrough infections by Trichosporon spp Tipo de documento : documento electrónico Autores : Isabel Cristina Ramírez Sánchez, Fecha de publicación : 2020 Títulos uniformes : Mycopathologia Idioma : Inglés (eng) Palabras clave : Antifungal  Breakthrough  Fungemia  Trichosporon asahii  Trichosporonosis  Yeast Resumen : Introduction: Cases of invasive Trichosporon infections have increasingly emerged; it is now the second leading cause of yeast bloodstream infections after Candida spp., particularly in the immunosuppressed population, where it often causes breakthrough fungemia with high mortality. Methods: We present a case report of a breakthrough Trichosporon asahii infection in a patient with acute myeloid leukemia and review all of the cases of breakthrough Trichosporon spp. infections published in the literature to date. Results: We extracted 68 cases of breakthrough Trichosporon spp. infections, wherein 95.5% patients had hematological malignancy, 61.8% of them occurred in the presence of echinocandins, 22% of triazoles, 13.2% of amphotericin and 3% of other combinations of antifungals. The most prevalent manifestation was fungemia (94%); 82.8% of these were associated with the presence of a central venous catheter. The overall mortality was 68.7%; the patients who survived recovered from the neutropenic event. Conclusions: Invasive trichosporonosis is an acute fatal condition that occurs in immunosuppressed patients, usually under antifungal selective pressure. Typically, neutropenia and its underlying diseases are associated with adverse outcomes. Mención de responsabilidad : I Ramírez, D Moncada Referencia : Mycopathologia. 2020 Apr;185(2):377-388. DOI (Digital Object Identifier) : 10.1007/s11046-019-00416-w PMID : 31853871 En línea : http://link.springer.com/10.1007/s11046-019-00416-w Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5078 Fatal disseminated infection by Trichosporon asahii under voriconazole therapy in a patient with acute myeloid leukemia: a review of breakthrough infections by Trichosporon spp [documento electrónico] / Isabel Cristina Ramírez Sánchez,  . - 2020. Obra : Mycopathologia Idioma : Inglés (eng) Palabras clave : Antifungal  Breakthrough  Fungemia  Trichosporon asahii  Trichosporonosis  Yeast Resumen : Introduction: Cases of invasive Trichosporon infections have increasingly emerged; it is now the second leading cause of yeast bloodstream infections after Candida spp., particularly in the immunosuppressed population, where it often causes breakthrough fungemia with high mortality. Methods: We present a case report of a breakthrough Trichosporon asahii infection in a patient with acute myeloid leukemia and review all of the cases of breakthrough Trichosporon spp. infections published in the literature to date. Results: We extracted 68 cases of breakthrough Trichosporon spp. infections, wherein 95.5% patients had hematological malignancy, 61.8% of them occurred in the presence of echinocandins, 22% of triazoles, 13.2% of amphotericin and 3% of other combinations of antifungals. The most prevalent manifestation was fungemia (94%); 82.8% of these were associated with the presence of a central venous catheter. The overall mortality was 68.7%; the patients who survived recovered from the neutropenic event. Conclusions: Invasive trichosporonosis is an acute fatal condition that occurs in immunosuppressed patients, usually under antifungal selective pressure. Typically, neutropenia and its underlying diseases are associated with adverse outcomes. Mención de responsabilidad : I Ramírez, D Moncada Referencia : Mycopathologia. 2020 Apr;185(2):377-388. DOI (Digital Object Identifier) : 10.1007/s11046-019-00416-w PMID : 31853871 En línea : http://link.springer.com/10.1007/s11046-019-00416-w Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=5078

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD001308	AC-2020-012	Archivo digital	Producción Científica	Artículos científicos	Disponible